ECM Therapeutics, Inc. — Form D/A
ECM Therapeutics, Inc. of WARRENDALE, PA, a company, filed a Form D amendment with the SEC on 2022-09-14. The offering totals $20.0M, of which $15.9M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-09-14
- Form: D/A
- Accession: 0001743104-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $20.0M
- Amount sold: $15.9M
- Remaining: $4.1M
- Investors: 147
- Date of first sale: 2018-05-28
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-314165
Issuer
- Name: ECM Therapeutics, Inc.
- CIK: 0001743104
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 118 MARSHALL DRIVE, WARRENDALE, PA, 15086
- Phone: 724-242-7106
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Katie F Collins | Director | Warrendale, PA |
| Katie F Collins | Executive Officer | Warrendale, PA |
| Christine F Sheehy | Executive Officer | Warrendale, PA |
| Jenna F Dziki | Executive Officer | Warrendale, PA |
| Stephen F Badylak | Director | Warrendale, PA |
| Stephen F Badylak | Executive Officer | Warrendale, PA |
| George F Hussey | Executive Officer | Warrendale, PA |
| Lindsey F Saldin | Executive Officer | Warrendale, PA |
| PAUL F FAGAN | Director | WARRENDALE, PA |
| PAUL F FAGAN | Executive Officer | WARRENDALE, PA |
Other filings by this issuer (7)
More